Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 186 citations
Electronic publication date
December 24, 2013

View on Pubmed.gov 23675754 | View on doi.org 10.1021/pr40033...

Metabonomics identifies serum metabolite markers of colorectal cancer.

Search for publications in this journal J Proteome Res - 12(6):3000-9

  • Binbin Tan

    Search for this expert
    1
  • Yunping Qiu
  • Xia Zou

    Search for this expert
  • Tianlu Chen

    Search for this expert
  • Guoxiang Xie
  • Yu Cheng

    Search for this expert
  • Taotao Dong

    Search for this expert
  • Linjing Zhao

    Search for this expert
  • Bo Feng

    Search for this expert
  • Xiaofang Hu

    Search for this expert
  • Lisa X Xu

    Search for this expert
  • Aihua Zhao

    Search for this expert
  • Menghui Zhang

    Search for this expert
  • Guoxiang Cai

    Search for this expert
  • Sanjun Cai

    Search for this expert
  • Zhanxiang Zhou
  • Minhua Zheng

    Search for this expert
  • Yan Zhang

    Search for this expert
  • Wei Jia

Abstract

Recent studies suggest that biofluid-based metabonomics may identify metabolite markers promising for colorectal cancer (CRC) diagnosis. We report here a follow-up replication study, after a previous CRC metabonomics study, aiming to identify a distinct serum metabolic signature of CRC with diagnostic potential. Serum metabolites from newly diagnosed CRC patients (N = 101) and healthy subjects (N = 102) were profiled using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) and ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS). Differential metabolites were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1) and the Mann-Whitney U test (p < 0.05). With a total of 249 annotated serum metabolites, we were able to differentiate CRC patients from the healthy controls using an orthogonal partial least-squares-discriminant analysis (OPLS-DA) in a learning sample set of 62 CRC patients and 62 matched healthy controls. This established model was able to correctly assign the rest of the samples to the CRC or control groups in a validation set of 39 CRC patients and 40 healthy controls. Consistent with our findings from the previous study, we observed a distinct metabolic signature in CRC patients including tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and gut flora metabolism. Our results demonstrated that a panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC.

References

CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36

J Proteome Res. 2009 Jan;8(1):352-61

CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1

Mol Cell Proteomics. 2009 Mar;8(3):558-70

Cited by 186 citations (total)

Journal Article

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.

Electronic publication date July 3, 2021

Search for publications in this journal Cancers (Basel)

Samantha Di Donato [...] Laura Biganzoli et al.

Adjuvant treatment for patients with early stage colorectal cancer (eCRC) is currently based on suboptimal risk stratification, especially for elderly...

Journal Article

Effect of Citric Acid Cycle Genetic Variants and Their Interactions with Obesity, Physical Activity and Energy Intake on the Risk of Colorectal Cancer: Results from a Nested Case-Control Study in the UK Biobank.

Electronic publication date October 16, 2020

Search for publications in this journal Cancers (Basel)

Sooyoung Cho [...] Aesun Shin et al.

Colorectal cancer is a common malignancy worldwide. Physical activity and a healthy diet contribute to energy balance and have been...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances